All News Incyte Corporation

Equities

INCY

US45337C1027

Market Closed - Nasdaq Other stock markets 21:00:00 29/04/2024 BST			5-day change	1st Jan Change
52.56 ^USD	+1.70%		+1.23%	-16.29%

04-24	Oppenheimer Adjusts Incyte Price Target to $84 From $92, Maintains Outperform Rating	MT
04-23	Transcript : Escient Pharmaceuticals, Inc., Incyte Corporation - M&A Call

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

'Shadow Trading' Verdict A Reminder For Companies To Review Insider Trading Policies And Train Insiders	04-29	AQ
SEC Secures Groundbreaking Win In Shadow Trading Insider Trading Case	04-28	AQ
"Shadow Trading" Is Insider Trading: Jury Establishes Liability In Historic Shadow Trading Case	04-24	AQ
Oppenheimer Adjusts Incyte Price Target to $84 From $92, Maintains Outperform Rating	04-24	MT
Transcript : Escient Pharmaceuticals, Inc., Incyte Corporation - M&A Call	04-23
Incyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-in-Class Oral MRGPR Antagonists	04-23	BU
SEC Wins Novel 'Shadow Trading' Trial Against Biopharma Executive	04-23	AQ
Incyte Corporation entered into a definitive agreement to acquire Escient Pharmaceuticals, Inc. from a group of shareholders for $750 million.	04-22	CI
BMO Capital Adjusts Price Target on Incyte to $56 From $64	04-19	MT
Incyte to Report First Quarter Financial Results	04-11	BU
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(4) - March 29, 2024	04-01	AQ
Incyte, China Medical System Sign Collaboration, License Agreement	04-01	MT
Incyte and CMS Announce Collaboration and License Agreement for Povorcitinib, an Oral JAK1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia	04-01	BU
Incyte Corporation and China Medical System Holdings Limited Announce Collaboration and License Agreement for Povorcitinib, an Oral Jak1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia	04-01	CI
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	03-29	BU
Trial of Insider Trading Case Against Former Medivation Employee Begins in California	03-26	MT
SEC v Panuwat: The SEC's Novel "Shadow Trading" Insider Trading Case Goes To Trial	03-19	AQ
Incyte's Povorcitinib Potentially Suited for Hidradenitis Suppurativa, Prurigo Nodularis, RBC Says	03-12	MT
Transcript : Incyte Corporation - Shareholder/Analyst Call	03-11
Incyte Presents New Late-Breaking Data from Phase 2 Study Evaluating Povorcitinib in Patients with Prurigo Nodularis	03-10	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Incyte Corporation : Is a big change imminent?

October 26, 2023 at 03:00 pm